Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 17.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 145,723 shares of the company’s stock after selling 30,021 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Larimar Therapeutics were worth $1,057,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. RA Capital Management L.P. acquired a new position in shares of Larimar Therapeutics during the first quarter worth approximately $45,884,000. Janus Henderson Group PLC boosted its position in shares of Larimar Therapeutics by 52.2% during the first quarter. Janus Henderson Group PLC now owns 4,020,965 shares of the company’s stock worth $30,459,000 after buying an additional 1,379,900 shares during the period. Vanguard Group Inc. boosted its position in shares of Larimar Therapeutics by 62.7% during the first quarter. Vanguard Group Inc. now owns 2,367,701 shares of the company’s stock worth $17,971,000 after buying an additional 912,458 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Larimar Therapeutics by 57.2% during the second quarter. Bank of New York Mellon Corp now owns 134,877 shares of the company’s stock worth $978,000 after buying an additional 49,102 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Larimar Therapeutics by 74.6% during the second quarter. Rhumbline Advisers now owns 54,936 shares of the company’s stock worth $398,000 after buying an additional 23,475 shares during the period. Institutional investors and hedge funds own 91.92% of the company’s stock.

Larimar Therapeutics Price Performance

LRMR stock opened at $6.99 on Friday. Larimar Therapeutics, Inc. has a 52-week low of $2.18 and a 52-week high of $13.68. The company has a 50-day moving average of $7.30 and a two-hundred day moving average of $7.76. The stock has a market capitalization of $446.03 million, a price-to-earnings ratio of -6.24 and a beta of 0.98.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.02). Equities analysts expect that Larimar Therapeutics, Inc. will post -1.39 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. HC Wainwright assumed coverage on Larimar Therapeutics in a research report on Wednesday, October 2nd. They set a “buy” rating and a $15.00 price objective for the company. Robert W. Baird assumed coverage on Larimar Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $16.00 target price for the company. Wedbush assumed coverage on Larimar Therapeutics in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 target price for the company. Finally, Baird R W upgraded Larimar Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Larimar Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $19.50.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.